Company profile
UK company 13237941, incorporated on 2 March 2021.
MitoRx Therapeutics - First-in-class mitochondrial protective therapeutics
Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. Mito Rx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
Company number 13237941
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
MitoRx Therapeutics develops mitochondrial treatments for rare neuromuscular disorders and metabolic disease.
Developing revolutionary mitochondrial-protective therapeutics Reversing mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration
This a newly incorporated company, in which co-applicant (Prof Matt Whiteman) is the Chief Scientific Officer. They are developing a pipeline of novel compounds for application in a variety of disease areas (https://www.mitorxtherapeutics.com/).
N/A
Seed round over-subscribed (March 2022); seed extension December 2023; https://ukinnovationscienceseedfund.co.uk/mitorx-therapeutics-announces-close-of-seed-extension-financing-round-to-advance-its-mitochondrial-protective-therapeutics-to-treat-degenerative-diseases/; new patents filed. Further top up funding (7 figures) Q1 2025
